KRAS and lung adenocarcinoma: Hence, we examined if CDK9 inhibitors can eliminate lung adenocarcinoma cells that are resistant to the third-generation EGFR inhibitor, Osimertinib, or the recently developed K-Ras G12C inhibitor, AMG510 (Sotorasib).